文献速递小儿泌尿与泌尿修复前列腺增生与排尿功能障碍

经皮电神经刺激联合奥昔布宁优于单药治疗儿童急迫性尿失禁:一项随机安慰剂对照研究

Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study.
PubMed 文献 · J Urol · 2017-03-19

该随机安慰剂对照研究纳入66例平均年龄7.3±1.6岁的急迫性尿失禁患儿,随机分为联合治疗组、经皮电神经刺激单药组和奥昔布宁单药组,干预10周。联合治疗组治疗应答概率较奥昔布宁单药组高83%(p=0.05),在减少每周尿湿天数、尿失禁严重程度和每日排尿频率方面显著优于经皮电神经刺激单药组。

要点

  • 联合治疗组较奥昔布宁单药组治疗应答概率高83%(p=0.05)。
  • 联合治疗组较经皮电神经刺激单药组每周尿湿天数平均减少2.28天(CI -4.06至-0.49)。
  • 经皮电神经刺激与奥昔布宁所致排尿后残余尿大于20 ml的风险降低相关。

核心结论

  • 经皮电神经刺激联合奥昔布宁治疗儿童急迫性尿失禁优于经皮电神经刺激或奥昔布宁单药治疗,但后者仅达到临界统计学显著性。
  • 经皮电神经刺激与奥昔布宁所致排尿后残余尿大于20 ml的风险降低相关。

研究设计与样本

  • 随机安慰剂对照研究,纳入66例诊断为急迫性尿失禁的儿童,平均±标准差年龄7.3±1.6岁,随机分为3组。
  • 第1组22例接受经皮电神经刺激联合活性奥昔布宁;第2组21例接受活性经皮电神经刺激联合安慰剂奥昔布宁;第3组23例接受活性奥昔布宁联合安慰剂经皮电神经刺激。
  • 经皮电神经刺激或安慰剂刺激置于骶部S2至S3流出区域,每日2小时,联合奥昔布宁5 mg活性药或安慰剂每日两次,干预周期10周。

主要发现

  • 联合治疗组较奥昔布宁单药组治疗应答概率高83%(p=0.05)。
  • 联合治疗组较经皮电神经刺激单药组每周尿湿天数平均差异-2.28(CI -4.06至-0.49)。
  • 联合治疗组较经皮电神经刺激单药组尿失禁严重程度平均差异-3.11(CI -5.98至-0.23)。
  • 联合治疗组较经皮电神经刺激单药组每日排尿频率平均差异-2.82(CI -4.48至-1.17)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated whether combination therapy with transcutaneous electrical nerve stimulation and oxybutynin results in a superior treatment response compared to either therapy alone in children with urge incontinence. MATERIALS AND METHODS: In this placebo controlled study 66 children with a mean ± SD age of 7.3 ± 1.6 years who were diagnosed with urge incontinence were randomized to 3 treatment groups. Group 1 consisted of 22 children undergoing transcutaneous electrical nerve stimulation plus active oxybutynin administration. Group 2 included 21 children undergoing active transcutaneous electrical nerve stimulation plus placebo oxybutynin administration. Group 3 consisted of 23 children undergoing active oxybutynin administration plus placebo transcutaneous electrical nerve stimulation. The children received active or placebo transcutaneous electrical nerve stimulation over the sacral S2 to S3 outflow for 2 hours daily in combination with 5 mg active or placebo oxybutynin twice daily. The intervention period was 10 weeks. Primary outcome was number of wet days weekly. Secondary outcomes were severity of incontinence, frequency, maximum voided volume over expected bladder capacity for age, average voided volume over expected bladder capacity for age and visual analogue scale score. RESULTS: Combination therapy was superior to oxybutynin monotherapy, with an 83% greater chance of treatment response (p = 0.05). Combination therapy was also significantly more effective than transcutaneous electrical nerve stimulation monotherapy regarding reduced number of wet days weekly (mean difference -2.28, CI -4.06 to -0.49), severity of incontinence (-3.11, CI -5.98 to -0.23) and daily voiding frequency (-2.82, CI -4.48 to -1.17). CONCLUSIONS: Transcutaneous electrical nerve stimulation in combination with oxybutynin for childhood urge incontinence was superior to monotherapy consisting of transcutaneous electrical nerve stimulation or oxybutynin, although the latter only reached borderline statistical significance. Furthermore, transcutaneous electrical nerve stimulation was associated with a decreased risk of oxybutynin induced post-void residual urine greater than 20 ml.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Borch L, Hagstroem S, Kamperis K, et al. Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study. J Urol. 2017. PMID: 28327453. doi:10.1016/j.juro.2017.03.117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。